跳至主要内容
临床试验/NCT04652843
NCT04652843终止不适用

Single-center Pathophysiological Study of the Role of Inflammation, Changes in the Intestinal Epithelial Barrier and the Intestinal Microbiota in Parkinson's Disease

Nantes University Hospital1 个研究点 分布在 1 个国家目标入组 77 人开始时间: 2020年12月17日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
入组人数
77
试验地点
1
主要终点
TNF-α

研究概览

简要总结

Converging evidence from the literature suggests that digestive inflammation may play a role in the development of Parkinson's disease (PD). The investigators showed in the laboratory in a pilot study that PD patients have digestive inflammation and that the level of inflammation was inversely related to the length of the disease course. This digestive inflammation could be at the origin of an increased intestinal permeability in a subpopulation of parkinsonian patients, cause or consequence of modifications of the intestinal microbiota, thus offering a potential portal of entry for a pathogen according to Braak's theory. To opponents of this theory, it could also reflect the spread of inflammation from the Central nervous System to the Enteral Nervous System (ENS), via the brain-gut axis.

Investigators' hypothesis is that digestive inflammation occurs very early in Parkinson's disease and that it is associated with hyperpermeability of the intestinal epithelial barrier and a change in the intestinal microbiota composition. The investigators propose to study the inflammation markers in the ENS of patients with a pre-motor form of PD (idiopathic Rapid Eye Movement (REM) sleep behavior disorder, n = 20), early-stage PD (<5 years, without dopatherapy, n = 20), more advanced PD (> 5 years, n = 20) and control subjects (n = 20), on colonic biopsies taken during a rectosigmoidoscopy or a coloscopy. Intestinal permeability will be measured by ex-vivo techniques (in a Ussing chamber), the composition of the microbiota will be established by sequencing 16s RNA and the lesional load of phosphorylated alpha-synuclein will be evaluated by immunohistochemistry. All of these parameters will be correlated with clinical data on the severity of PD: duration of development, age, total Unified Parkinson's Disease Rating Scale (UPDRS) motor score and axial sub-score, cognitive tests (Montreal Cognitive Assessment, MoCA), existence of a probable idiopathic REM sleep behavior disorder (REM Sleep Behavior Disorder Screening Questionnaire RBDSQ), olfactory tests, complaint of dysautonomia (SCales for Outcomes in Parkinson's disease - autonomic dysfunction, SCOPA-Aut).

The analysis of inflammation markers, the intestinal barrier and the microbiota could be a first step making it possible to formulate physiopathological hypotheses on the development of PD, to propose predictive biomarkers of the disease and its severity and to design early interventions in the hope of modifying the evolutionary course of the pathological process.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Parkinson's Disease patients :
  • •patients with Parkinson's disease according to the criteria of the United Kingdom Parkinson's disease survey brain bank (UKPDSBB)
  • •aged over 18 years
  • •who have given their consent to participate in this study
  • •Idiopathic REM sleep behavior disorders patients:
  • •patients with an Idiopathic REM sleep behavior disorder confirmed by video-polysomnography (International Classification of Sleep Disorders-3 criteria), not explained by a pathology (narcolepsy, brainstem injury, neurodegenerative disease)
  • •aged over 18 years
  • •having given their consent to participate in this study
  • •patients undergoing coloscopy for family screening for digestive polyps
  • •aged over 18
  • •who have given their consent to participate in this study

排除标准

  • •dementia (MINI MENTAL STATE EXAMINATION score <24)
  • •history of authenticated colonic disease (inflammatory disease, adenocarcinoma) or functional colopathy in control subjects or having preceded the first signs of Parkinson's Disease or Idiopathic REM sleep behavior disorder for more than 5 years, respectively in Parkinson's Disease and Idiopathic REM sleep behavior disorder patients
  • •history of prescription of antibiotic treatment, acute gastrointestinal illness or hospitalization for an acute medical pathology or for a surgical procedure in the last month
  • •anticoagulant treatment or coagulopathy
  • •pregnant or breastfeeding women, woman not benefiting from effective contraception if of childbearing age
  • •adults under tutorship, curatorship or under legal protection
  • •For patients with Idiopathic REM sleep behavior disorder:
  • •presence of Parkinson's Disease according to United Kindom Parkinson's Disease Brain Bank criteria
  • •For control:
  • •presence of a Parkinson's Disease according to United Kindom Parkinson's Disease Brain Bank criteria
  • •complaint of nighttime unrest in favor of a probable Idiopathic REM sleep behavior disorder

研究组 & 干预措施

Idiopathic REM sleep behavior disorders

Other

Group of 20 Patients with an Idiopathic REM sleep behavior disorder confirmed by video-polysomnography (International Classification of Sleep Disorders-3 criteria), not explained by a pathology (narcolepsy, brainstem injury, neurodegenerative disease)

干预措施: Rectosignoidoscopy (Procedure)

Idiopathic REM sleep behavior disorders

Other

Group of 20 Patients with an Idiopathic REM sleep behavior disorder confirmed by video-polysomnography (International Classification of Sleep Disorders-3 criteria), not explained by a pathology (narcolepsy, brainstem injury, neurodegenerative disease)

干预措施: Coloscopy (Procedure)

Beginning Parkinson's disease

Other

Group of 20 patients with Parkinson's Disease which has been progressing for less than 5 years and who have not received dopatherapy

干预措施: Rectosignoidoscopy (Procedure)

Beginning Parkinson's disease

Other

Group of 20 patients with Parkinson's Disease which has been progressing for less than 5 years and who have not received dopatherapy

干预措施: Coloscopy (Procedure)

Parkinson's disease state Phase

Other

Group of 20 patients with Parkinson's Disease for more than 5 years

干预措施: Rectosignoidoscopy (Procedure)

Parkinson's disease state Phase

Other

Group of 20 patients with Parkinson's Disease for more than 5 years

干预措施: Coloscopy (Procedure)

Control

Other

Group of 20 patients undergoing coloscopy for family screening for digestive polyps

干预措施: Coloscopy (Procedure)

结局指标

主要结局

TNF-α

时间窗: In the three months following the inclusion

TNF-α in colonic biopsies measured by ELISA

次要结局

  • Montreal Cognitive Assessment score(At inclusion)
  • IL-17A(In the three months following the inclusion)
  • IL-18(In the three months following the inclusion)
  • Age(At inclusion)
  • Total Unified Parkinson Disease Rating Scale motor score(At inclusion)
  • IFN-γ(In the three months following the inclusion)
  • IFN-α2(In the three months following the inclusion)
  • IL-23(In the three months following the inclusion)
  • IL-33(In the three months following the inclusion)
  • Permeability slopes for sulfonic acid(In the three months following the inclusion)
  • Quantification of phosphorylated alpha-synuclein(In the three months following the inclusion)
  • Presence or absence of a probable Idiopathic REM sleep behavior disorders(At inclusion)
  • MCP-1 (CCL2)(In the three months following the inclusion)
  • Duration of progression(At inclusion)
  • Unified Parkinson Disease Rating Scale axial sub-score(At inclusion)
  • IL-6(In the three months following the inclusion)
  • IL-1β(In the three months following the inclusion)
  • IL-8 (CXCL8)(In the three months following the inclusion)
  • IL-10(In the three months following the inclusion)
  • IL-12p70(In the three months following the inclusion)
  • Diversity of the intestinal microbiota(In the three months following the inclusion)
  • Relative abundance of the intestinal microbiota(In the three months following the inclusion)
  • Olfactory tests(At inclusion)
  • Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction score(At inclusion)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验